Cancer Doctor Leading the Attack on Astronomical Drug Prices

LessThunk: This is a 200K per patient per year problem. Root causes need to be addressed..  “systemic profiteering” driven by the loose interplay between “public compassion” and “vested interest”.. wholesale restructuring is the answer here, there is no incremental solution to this..

The cost debate is intensifying as drug companies such as AstraZeneca,
Roche, Bristol-Myers Squibb, and Merck race to develop medications that
harness the body’s own immune system to fight various forms of cancer.


Categorised as: economy

Posted by: Kramer

Comments are disabled on this post

Comments are closed.

Disclaimers – All content here is NOT presented as investment advice; LessThunk is NOT endorsing any website or specific investment by displaying external links.

We may or may-not (coincidentally) hold some quantity of stock or other investment related to any given post, no endorsement is implied in any sense.